



MARAPHARM VENTURES INC.

NEWS RELEASE

MARAPHARM UPGRADES AND LISTS ON THE U.S. OTCQB® VENTURE MARKET

Vancouver, British Columbia, Canada – December 10, 2015 (CSE:MDM, FSE:2M0, OTCQB:MRPHF) – Marapharm Ventures Inc. (“Marapharm” or the “Company”) (www.marapharm.com) is pleased to announce that its shares have commenced trading under the symbol “MRPHF” on the OTCQB® venture market in the United States. The OTCQB® venture stage marketplace is for entrepreneurial and development stage U.S. and international companies such as Marapharm. The shares of the Company previously traded on the OTCPink® open marketplace.

To be eligible, companies must be current in their reporting, listed on an international stock exchange such as the Canadian Stock Exchange (“CSE”) and undergo an annual certification process that verifies management, director, controlling shareholders and shares outstanding. These standards provide a strong baseline of transparency, as well as the technology and regulation to improve greater information and disclosure, trading experience and improved investor confidence through current verified information available on www.otcm Markets.com. Moving to the OTCQB® now provides investors transparent pricing and more efficient trading through full depth of book with real time level 2 quotes.

The Company trades on the CSE under the symbol “MDM”, and the Company also trades on the Frankfurt Stock Exchange under the symbol 2M0. The Frankfurt Stock Exchange is the world's third largest organized exchange-trading market in terms of turnover and dealings in securities behind only the Nasdaq and the New York Stock Exchanges.

“The directors of Marapharm believe that the multiple stock exchange listings, marks a further step in Marapharm’s commitment to its shareholders to enhance the liquidity of the Company's common shares and is another initiative planned to further increase market awareness for the Company. North American, European and especially German-based investors have an established interest and expertise in emerging and developing industry companies,” stated Les Kjosness, President of Marapharm. “The Company is preparing for the global markets, which is strategically consistent to create a global entity by pursuing commercial ventures in the developing medical marijuana sector.”

About Marapharm Ventures Inc.

Marapharm trades under the symbols MDM on the Canadian Securities Exchange (“CSE”), 2M0 on the Frankfurt Stock Exchange (“FSE”) and MRPHF on the U.S OTCQB® marketplace.

Marapharm (www.marapharm.com) and its wholly-owned subsidiary in Canada, Marapharm Inc., and its wholly-owned subsidiary in the United States, Marapharm Las Vegas LLC, is engaged in the development, production of and commercialization of phytocannabinoid-based pharmaceutical products in Canada and the United States. The Company is at the security clearance stage with Health Canada to become a licensed producer under the Marijuana for Medical Purposes Regulations (MMPR) issued pursuant to the *Controlled*

Drugs and Substances Act (Canada). The company also intends to focus its development and growth strategy in Colorado, Nevada and California and plans to acquire - grow, production and dispensary licenses in the United States.

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website at www.thecse.ca and the SEDAR website at www.sedar.com under the profile for Marapharm Ventures Inc.

On behalf of the Board
“Les Kjosness”
President & Director

For further information, please contact:

Les Kjosness, President
Tel: +1-604-952-6676
Email: les@marapharm.com

Terry Yuck, Investor Relations
Bayside Management Ltd.
Telephone: +1-403-861-5775
Email: terry@marapharm.com

Neither the CSE, the FSE nor the OTCQB® have approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

Various risks and other factors could cause actual results, and actual events that occur, to differ materially from those contemplated by the forward looking statements, such as whether Marapharm is able to meet price, performance, quality and delivery requirements. Although Marapharm believes that the expectations represented by any forward-looking statements and forward-looking information contained herein are reasonable based on the information available to them on the date of this document, management cannot assure investors that actual results, performance or achievements will be consistent with these forward-looking statements or forward-looking information. Marapharm undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.